Although the development of combination therapies for Alzheimer’s disease is highly recommended, [45,46] until now only combinations of approved symptomatic therapies with memantine and acetylcholinesterase inhibitors have been investigated in detail [46,47,48,49,50]. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.